Drug Profile
ORG 50189
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Organon
- Developer Schering-Plough
- Class
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Neurological-disorders in USA
- 20 Oct 2009 Phase-I development is ongoing in USA
- 12 Dec 2007 Phase-I clinical trials in Neurological disorders in USA (unspecified route)